A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

Summary SGN‐30, a chimeric anti‐CD30 monoclonal antibody, has demonstrated potent preclinical antitumour activity in both Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). We conducted an open‐label, Phase II study to determine the safety and objective response rate of SGN‐30 in 79 pa...

Full description

Saved in:

Bibliographic Details
Published in:	British journal of haematology Vol. 146; no. 2; pp. 171 - 179
Main Authors:	Forero‐Torres, Andres, Leonard, John P., Younes, Anas, Rosenblatt, Joseph D., Brice, Pauline, Bartlett, Nancy L., Bosly, Andre, Pinter‐Brown, Lauren, Kennedy, Dana, Sievers, Eric L., Gopal, Ajay K.
Format:	Journal Article
Language:	English
Published:	Oxford, UK Blackwell Publishing Ltd 01.07.2009 Blackwell
Subjects:	Adult Aged anaplastic large cell lymphoma anaplastic lymphoma kinase Antibodies, Anti-Idiotypic - blood Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antineoplastic Agents - administration & dosage anti‐CD30 antibody Biological and medical sciences Chimerin Proteins - blood Dose-Response Relationship, Drug Female Hematologic and hematopoietic diseases Hodgkin Disease - therapy Hodgkin lymphoma Humans Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphoma, Large-Cell, Anaplastic - drug therapy Male Medical sciences Middle Aged monoclonal antibody Young Adult Hematology anti-CD30 antibody Anaplastic cell lymphoma Hodgkin disease Malignant hemopathy Large cell lymphoma Monoclonal antibody Non Hodgkin lymphoma Treatment Lymphoproliferative syndrome Phase II trial anaplastic large cell lymphoma Anaplastic lymphoma kinase Cancer Hodgkin lymphoma
ISSN:	0007-1048, 1365-2141, 1365-2141
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!